Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Seligson

Showing results (191-200 of 195) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 195 results.
Journal for Immunotherapy of Cancer|September 29, 2024
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analysesNathan D Seligson, James L Chen, Austin C Goodrich, et al.
The Oncologist|April 26, 2019
Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaKate Lynn J Bill, Nathan D Seligson, John L Hays, et al.
Journal of the American Medical Informatics Association : JAMIA|September 5, 2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarityNathan D Seligson, Jeremy L Warner, William S Dalton, et al.
Journal for Immunotherapy of Cancer|November 11, 2025
Systemic mRNA vaccines elicit rapid immune activation in canine brain tumorsSheila Carrera-Justiz, Mahya Aghaee, Sadeem Qdaisat, et al.
Nature Communications|May 6, 2025
Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypesAlex Soupir, Oscar E Ospina, Oliver Hampton, et al.
Pageof 20

Showing results (191-200 of 195) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 195 results.
Journal for Immunotherapy of Cancer|September 29, 2024
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analysesNathan D Seligson, James L Chen, Austin C Goodrich, et al.
The Oncologist|April 26, 2019
Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaKate Lynn J Bill, Nathan D Seligson, John L Hays, et al.
Journal of the American Medical Informatics Association : JAMIA|September 5, 2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarityNathan D Seligson, Jeremy L Warner, William S Dalton, et al.
Journal for Immunotherapy of Cancer|November 11, 2025
Systemic mRNA vaccines elicit rapid immune activation in canine brain tumorsSheila Carrera-Justiz, Mahya Aghaee, Sadeem Qdaisat, et al.
Nature Communications|May 6, 2025
Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypesAlex Soupir, Oscar E Ospina, Oliver Hampton, et al.
Pageof 20